Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 1.00 |
| ▸ | PPARD | Q03181 | 8/20 | 1.00 |
| ▸ | PPARA | Q07869 | 7/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402468 | 0.95 | PPARG (1.00) | PPARGPPARDPPARARECQLPOLB | |
| SCHEMBL5404218 | 0.93 | PPARG (0.86) | PPARGPPARDPPARARECQLPOLB | |
| SCHEMBL6382468 | 0.90 | PPARG (0.81) | PPARGPPARDPPARARECQL | |
| SCHEMBL5411467 | 0.86 | PPARG (0.74) | PPARGPPARDPPARAALDH1A1 | |
| SCHEMBL22231523 | 0.84 | PPARG (0.72) | PPARGPPARDPPARARECQLHDAC1 | |
| SCHEMBL6704879 | 0.83 | PPARG (0.71) | PPARGPPARDPPARA | |
| SCHEMBL5410720 | 0.82 | PPARG (1.00) | PPARGPPARDPPARAKDM4EMAPK1 | |
| SCHEMBL5414199 | 0.81 | PPARG (0.76) | PPARGPPARDPPARAALDH1A1 | |
| SCHEMBL5389190 | 0.81 | PPARG (0.72) | PPARGPPARDPPARAKDM4EALDH1A1 | |
| SCHEMBL7033327 | 0.81 | PPARG (0.67) | PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2007-06-21 | — | — | US | disclosed |
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2007-06-21 | — | — | US | disclosed |
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2007-06-21 | — | — | US | disclosed |
| US-7192970-B2 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-03-20 | — | — | US | disclosed |
| US-7192970-B2 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-03-20 | — | — | US | disclosed |
| US-7192970-B2 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | CHIPSCREEN BIOSCIENCES, LTD. (CN) | 2007-03-20 | — | — | US | disclosed |
| US-20040138211-A1 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2004-07-15 | — | — | US | disclosed |
| WO-2004048338-A1 | NONCYCLIC 1,3-DICARBONYL COMPOUNDS AS DUAL PPAR AGONISTS WITH POTENT ANTIHYPERGLYCEMIC AND ANTIHYPERLIPIDEMIC ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142427-A1 | Noncyclic 1,3-Dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | GPR119, PPARG, PPARA | PPARG 2/4885PPARD 4/4885PPARA 3/4885 |
| US-20040138211-A1 | Noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity | PPARG, GPR119, PPARA | PPARG 1/4885PPARD 5/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.